

Anna K Renfrew

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2770892/publications.pdf>

Version: 2024-02-01

40
papers

2,572
citations

257450

24
h-index

289244

40
g-index

47
all docs

47
docs citations

47
times ranked

3169
citing authors

#	ARTICLE	IF	CITATIONS
1	The $\text{Ru}(\text{acac})_2$ Complexes as a Trojan Horse for Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2008, 47, 3773-3776.	11.2	12
2	Metal complexes as a promising source for new antibiotics. <i>Chemical Science</i> , 2020, 11, 2627-2639.	7.4	290
3	Transition metal complexes with bioactive ligands: mechanisms for selective ligand release and applications for drug delivery. <i>Metallomics</i> , 2014, 6, 1324-1335.	2.4	170
4	Antiproliferative activity of chelating N,O- and N,N-ruthenium(ii) arene functionalised poly(propyleneimine) dendrimer scaffolds. <i>Dalton Transactions</i> , 2011, 40, 1158-1167.	3.3	148
5	Delivery and release of curcumin by a hypoxia-activated cobalt chaperone: a XANES and FLIM study. <i>Chemical Science</i> , 2013, 4, 3731.	7.4	130
6	Synthesis, Molecular Structure, and Anticancer Activity of Cationic Arene Ruthenium Metallarectangles. <i>Organometallics</i> , 2009, 28, 4350-4357.	2.3	118
7	Anticancer activity of multinuclear arene ruthenium complexes coordinated to dendritic polypyridyl scaffolds. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 3470-3476.	1.8	91
8	Influence of the Diketonato Ligand on the Cytotoxicities of $[\text{Ru}(\text{I}^6\text{-arene})(\text{R}^2\text{-acac})(\text{PTA})]^{2+}$ Complexes (PTA = Tj ETQqO 0.0 rgBT / Overlock 10	2.0	86
9	Dual Targeting of Hypoxic and Acidic Tumor Environments with a Cobalt(III) Chaperone Complex. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 11013-11021.	6.4	85
10	Harnessing the properties of cobalt coordination complexes for biological application. <i>Coordination Chemistry Reviews</i> , 2018, 375, 221-233.	18.8	84
11	Drug delivery of lipophilic pyrenyl derivatives by encapsulation in a water soluble metalla-cage. <i>Dalton Transactions</i> , 2010, 39, 8248.	3.3	82
12	Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. <i>Organometallics</i> , 2009, 28, 1165-1172.	2.3	79
13	Cobalt(III) Chaperone Complexes of Curcumin: Photoreduction, Cellular Accumulation and Light-Selective Toxicity towards Tumour Cells. <i>Chemistry - A European Journal</i> , 2015, 21, 15224-15234.	3.3	79
14	Discovery, Structure, and Anticancer Activity of an Iridium Complex of Diselenobenzoquinone. <i>Angewandte Chemie - International Edition</i> , 2010, 49, 7530-7533.	13.8	73
15	A luminescent ruthenium(ii) complex for light-triggered drug release and live cell imaging. <i>Chemical Communications</i> , 2015, 51, 14038-14041.	4.1	67
16	Tuning the Efficacy of Ruthenium(II)-Arene (RAPTA) Antitumor Compounds with Fluorinated Arene Ligands. <i>Organometallics</i> , 2009, 28, 5061-5071.	2.3	61
17	Arene-ruthenium complexes with ferrocene-derived ligands: Synthesis and characterization of complexes of the type $[\text{Ru}(\text{I}^6\text{-arene})(\text{NC}_5\text{H}_4\text{CH}_2\text{NHOC-C}_5\text{H}_4\text{FeC}_5\text{H}_5)\text{Cl}_2]$ and $[\text{Ru}(\text{I}^6\text{-arene})(\text{NC}_3\text{H}_3\text{N}(\text{CH}_2)_2\text{O}_2\text{C-C}_5\text{H}_4\text{FeC}_5\text{H}_5)\text{Cl}_2]$. <i>Journal of Organometallic Chemistry</i> , 2009, 694, 855-861.	1.8	54
18	Metabolization of $[\text{Ru}(\text{I}^6\text{-C}_6\text{H}_5\text{CF}_3)(\text{pta})\text{Cl}_2]$: a cytotoxic RAPTA-type complex with a strongly electron withdrawing arene ligand. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 919-927.	2.6	45

#	ARTICLE	IF	CITATIONS
19	Adding diversity to ruthenium(II) arene anticancer (RAPTA) compounds via click chemistry: The influence of hydrophobic chains. <i>Journal of Organometallic Chemistry</i> , 2011, 696, 772-779.	1.8	42
20	Use of Perfluorinated Phosphines to Provide Thermomorphic Anticancer Complexes for Heat-Based Tumor Targeting. <i>Inorganic Chemistry</i> , 2010, 49, 2239-2246.	4.0	35
21	Hypoxia-Responsive Cobalt Complexes in Tumor Spheroids: Laser Ablation Inductively Coupled Plasma Mass Spectrometry and Magnetic Resonance Imaging Studies. <i>Inorganic Chemistry</i> , 2017, 56, 9860-9868.	4.0	34
22	Towards Light-Activated Ruthenium Arene (RAPTA-type) Prodrug Candidates. <i>ChemBioChem</i> , 2019, 20, 2876-2882.	2.6	30
23	Photolabile Ruthenium(II) Purine Complexes: Phototoxicity, DNA Binding, and Light-Triggered Drug Release. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1679-1686.	2.0	28
24	Photolabile ruthenium complexes to cage and release a highly cytotoxic anticancer agent. <i>Journal of Inorganic Biochemistry</i> , 2018, 179, 146-153.	3.5	28
25	Synthesis and Anticancer Activity of Long-Chain Isonicotinic Ester Ligand-Containing Arene Ruthenium Complexes and Nanoparticles. <i>Journal of Cluster Science</i> , 2010, 21, 313-324.	3.3	23
26	Water-soluble arene ruthenium complexes containing pyridinethiolato ligands: Synthesis, molecular structure, redox properties and anticancer activity of the cations [(<i>l</i> -6-arene)Ru(<i>p</i> -SC ₅ H ₄ NH) ₃] ₂ ⁺ . <i>Journal of Organometallic Chemistry</i> , 2008, 693, 3419-3424.	1.8	22
27	Reversible magnetogenic cobalt complexes. <i>RSC Advances</i> , 2016, 6, 30021-30027.	3.6	19
28	Soluble Redox-Active Polymetallic Chains [(RuO(CO)(L)(bpy)) _m] _n (bpy = 2,2'-bipyridine, L = PrCN, Cl ⁻ ; m = 0, 1, 2; n = 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20). <i>Journal of Organometallic Chemistry</i> , 2008, 693, 3419-3424.	4.0	17
29	Ruthenium(II) Arene Compounds as Versatile Anticancer Agents. <i>Chimia</i> , 2009, 63, 217-219.	0.6	15
30	Synthesis and anticancer activity of chalcogenide derivatives and platinum(II) and palladium(II) complexes derived from a polar ferrocene phosphanylcarboxamide. <i>Applied Organometallic Chemistry</i> , 2010, 24, 392-397.	3.5	14
31	Synthesis and characterisation of the water soluble bis-phosphine complex [Ru(<i>l</i> -6-cymene)(PPh ₂ (<i>o</i> -C ₆ H ₄ O)-P ₂ -P ₂ O)(pta)] ⁺ and an investigation of its cytotoxic effects. <i>Comptes Rendus Chimie</i> , 2010, 13, 1144-1150.	0.5	14
32	The influence of the ancillary ligand on the potential of cobalt complexes to act as chaperones for hydroxamic acid-based drugs. <i>Dalton Transactions</i> , 2017, 46, 15897-15907.	3.3	14
33	Targeting curcumin to specific tumour cell environments: the influence of ancillary ligands. <i>Metallomics</i> , 2017, 9, 699-705.	2.4	13
34	Photolabile Ru Model Complexes with Chelating Diimine Ligands for Light-Triggered Drug Release. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 1469-1480.	2.0	10
35	Warburg Effect Targeting Co(III) Cytotoxin Chaperone Complexes. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2678-2690.	6.4	9
36	The effect of charge on the uptake and resistance to reduction of platinum complexes in human serum and whole blood models. <i>Metallomics</i> , 2020, 12, 1599-1615.	2.4	8

#	ARTICLE	IF	CITATIONS
37	Spectroscopic Approaches to Tracking Metal-based Drugs in Cells and Tissue. <i>Chimia</i> , 2017, 71, 112.	0.6	4
38	An easy electrochemical and chemical synthesis of [Ru(bpy)(CH ₃ CN) ₂ Cl ₂]: a synthon for heteroleptic tris(diimine) Ru(II) complexes. <i>Dalton Transactions</i> , 2008, , 5891.	3.3	2
39	Photolabile Ruthenium(II)-Purine Complexes: Phototoxicity, DNA Binding, and Light-Triggered Drug Release. <i>European Journal of Inorganic Chemistry</i> , 2017, 2017, 1538-1538.	2.0	0
40	Photolabile Ru Model Complexes with Chelating Diimine Ligands for Light-Triggered Drug Release. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 1447-1447.	2.0	0